Advanced Solid Tumors Clinical Trials

78 studies are recruiting for advanced solid tumors in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

   Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer l…

   Stage

   Phase 1

   Ages

   12 to 120

   Site

   University of Kansas, Fairway, Kansas

   Locations

   2 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04222413 on ClinicalTrials.gov

2. Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

   The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health, Scottsdale, Arizona

   Locations

   7 in total

   Run by

   Tagworks Pharmaceuticals BV

   See if you can join NCT06959706 on ClinicalTrials.gov

3. PAS-004 in Patients With Advanced Solid Tumors

   The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate diff…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   5 in total

   Run by

   Pasithea Therapeutics Corp.

   See if you can join NCT06299839 on ClinicalTrials.gov

4. GenSci143 in Participants With Advanced Solid Tumors

   A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

   Locations

   13 in total

   Run by

   Changchun GeneScience Pharmaceutical Co., Ltd.

   See if you can join NCT07252414 on ClinicalTrials.gov

5. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

   The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   California Research Institute (CRI), Los Angeles, California

   Locations

   45 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT07262619 on ClinicalTrials.gov

6. A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

   This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Scottsdale, Arizona

   Locations

   7 in total

   Run by

   Samsung Bioepis Co., Ltd.

   See if you can join NCT07524348 on ClinicalTrials.gov

7. A Study of BG-C477 in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Phoenix Cancer Center, Goodyear, Arizona

   Locations

   59 in total

   Run by

   BeOne Medicines

   See if you can join NCT06596473 on ClinicalTrials.gov

8. A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

   Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main g…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham ( Site 1005), Birmingham, Alabama

   Locations

   49 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06818643 on ClinicalTrials.gov

9. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

   A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

   Stage

   Phase 1

   Ages

   16 and older

   Site

   The City of Hope National Medical Center, Duarte, California

   Locations

   6 in total

   Run by

   SEED Therapeutics, Inc.

   See if you can join NCT07197554 on ClinicalTrials.gov

10. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    30 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07213791 on ClinicalTrials.gov

11. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Orlando, Florida

    Locations

    14 in total

    Run by

    Alterome Therapeutics, Inc.

    See if you can join NCT06835569 on ClinicalTrials.gov

12. JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

    This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    4 in total

    Run by

    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT06973564 on ClinicalTrials.gov

13. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site 111, Tucson, Arizona

    Locations

    107 in total

    Run by

    DualityBio Inc.

    See if you can join NCT05914116 on ClinicalTrials.gov

14. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Cancer Center, Duarte, California

    Locations

    55 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT06004245 on ClinicalTrials.gov

15. A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

    The purpose of this study is to investigate the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine (UCI) Health - UC Irvine Medical Center, Irvine, California

    Locations

    21 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06697197 on ClinicalTrials.gov

16. A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

    This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication cohorts'). Participants aged ≥18 years are planned to be enrolled. CBX-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    4 in total

    Run by

    Crossbow Therapeutics, Inc.

    See if you can join NCT07779798 on ClinicalTrials.gov

17. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale University - Yale University School of Medicine, New Haven, Connecticut

    Locations

    9 in total

    Run by

    EMD Serono Research & Development Institute, Inc.

    See if you can join NCT07360314 on ClinicalTrials.gov

18. A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

    This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    10 in total

    Run by

    Nutshell Therapeutics (Shanghai) Co., LTD.

    See if you can join NCT07060989 on ClinicalTrials.gov

19. A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

    This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START New York - Long Island, Lake Success, New York

    Locations

    8 in total

    Run by

    LigaChem Biosciences, Inc.

    See if you can join NCT07460375 on ClinicalTrials.gov

20. A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

    Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Dallas Fort Worth Cancer Center, Fort Worth, Texas

    Locations

    6 in total

    Run by

    Antares Therapeutics, Inc

    See if you can join NCT07767474 on ClinicalTrials.gov

21. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest /ID# 283487, Grand Rapids, Michigan

    Locations

    3 in total

    Run by

    AbbVie

    See if you can join NCT07807956 on ClinicalTrials.gov

22. A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

    Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced may mean the cancer has spread to nearby or other parts of the body. The cancer may not be able to be t…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    START San Antonio ( Site 0220), San Antonio, Texas

    Locations

    4 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07785609 on ClinicalTrials.gov

23. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

    A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    16 in total

    Run by

    Tyra Biosciences, Inc

    See if you can join NCT06915753 on ClinicalTrials.gov

24. Study of GS-2426 in Participants With Advanced Solid Tumors

    The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    6 in total

    Run by

    Gilead Sciences

    See if you can join NCT07601243 on ClinicalTrials.gov

25. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

    The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 as a monotherapy and in combination with bevacizumab (or a …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Denver, Aurora, Colorado

    Locations

    11 in total

    Run by

    Accent Therapeutics

    See if you can join NCT06799065 on ClinicalTrials.gov